The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Open accessAbstract
BACKGROUND: Induction of delta aminolevulinic acid synthase 1 ( ALAS1) gene expression and accumulation of neurotoxic intermediates result in neurovisceral attacks and disease manifestations in patients with acute intermittent porphyria, a rare inherited disease of heme biosynthesis. Givosiran is an investigational RNA interference therapeutic agent that inhibits hepatic ALAS1 synthesis. METHODS: We conducted a phase 1 trial of givosiran in patients with acute intermittent porphyria. In part A of the trial, patients without recent porphyria attacks (i.e., no attacks in the 6 months before baseline) were randomly assigned to receive a single subcutaneous injection of one of five ascending doses of givosiran (0.035, 0.10, 0.35, 1.0, or 2.5 mg per kilogram of body weight) or placebo. In part B, patients without recent attacks were randomly assigned to receive once-monthly injections of one of two doses of givosiran (0.35 or 1.0 mg per kilogram) or placebo (total of two injections 28 days apart). In part C, patients who had recurrent attacks were randomly assigned to receive injections of one of two doses of givosiran (2.5 or 5.0 mg per kilogram) or placebo once monthly (total of four injections) or once quarterly (total of two injections) during a 12-week period, starting on day 0. Safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy outcomes were evaluated. RESULTS: A total of 23 patients in parts A and B and 17 patients in part C underwent randomization. Common adverse events included nasopharyngitis, abdominal pain, and diarrhea. Serious adverse events occurred in 6 patients who received givosiran in parts A through C combined. In part C, all 6 patients who were assigned to receive once-monthly injections of givosiran had sustained reductions in ALAS1 messenger RNA (mRNA), delta aminolevulinic acid, and porphobilinogen levels to near normal. These reductions were associated with a 79% lower mean annualized attack rate than that observed with placebo (exploratory efficacy end point). CONCLUSIONS: Once-monthly injections of givosiran in patients who had recurrent porphyria attacks resulted in mainly low-grade adverse events, reductions in induced ALAS1 mRNA levels, nearly normalized levels of the neurotoxic intermediates delta aminolevulinic acid and porphobilinogen, and a lower attack rate than that observed with placebo. (Funded by Alnylam Pharmaceuticals; ClinicalTrials.gov number, NCT02452372 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Puy, H., Gouya, L., & Deybach, J.-C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61925-5 · Cited by 729
Recommendations for the Diagnosis and Treatment of the Acute Porphyrias
Anderson, K. E., Bloomer, J. R., Bonkovsky, H. L., Kushner, J. P., Pierach, C. A., Pimstone, N. R., & Desnick, R. J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00010 · Cited by 628
Self-citationBissell, D. M., Anderson, K. E., & Bonkovsky, H. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608634 · Cited by 399
Self-citationAn update of clinical management of acute intermittent porphyria
Pischik, E., & Kauppinen, R. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s48605 · Cited by 195
Update review of the acute porphyrias
Stein, P. E., Badminton, M. N., & Rees, D. C. (2017) · British Journal of Haematology · doi:10.1111/bjh.14459 · Cited by 170
Self-citationAcute hepatic porphyrias: Recommendations for evaluation and long‐term management
Balwani, M., Wang, B., Anderson, K. E., Bloomer, J. R., Bissell, D. M., Bonkovsky, H. L., Phillips, J. D., Desnick, R. J., & for the Porphyrias Consortium of the Rare Diseases Clinical Research Network (2017) · Hepatology · doi:10.1002/hep.29313 · Cited by 170
Self-citationChen, B., Solis-Villa, C., Hakenberg, J., Qiao, W., Srinivasan, R. R., Yasuda, M., Balwani, M., Doheny, D., Peter, I., Chen, R., et al. (2016) · Human Mutation · doi:10.1002/humu.23067 · Cited by 167
Self-citationPhase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria
D’Avola, D., López‐Franco, E., Sangro, B., Pañeda, A., Grosios, N., Gil-Fariña, I., Benito, A., Twisk, J., Paz, M., Ruiz, J. A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.012 · Cited by 144
Self-citationYasuda, M., Gan, L., Chen, B., Kadirvel, S., Yu, C., Phillips, J. D., New, M. I., Liebow, A., Fitzgerald, K. J., Querbes, W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406228111 · Cited by 133
Self-citationChan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.36 · Cited by 128
Self-citationNORDMANN, Y., Puy, H., Silva, V. D., et al. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.00189.x · Cited by 128
Pallet, N., Mami, I., Schmitt, C., Karim, Z., François, A., Rabant, M., Nochy, D., Gouya, L., Deybach, J., Xu-Dubois, Y., et al. (2015) · Kidney International · doi:10.1038/ki.2015.97 · Cited by 127
Stein, P. E., Badminton, M. N., Barth, J. H., et al. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563212474555 · Cited by 123
Self-citationSchmitt, C., Lenglet, H., Yu, A., Delaby, C., Benecke, A., Lefèbvre, T., Lettéron, P., Paradis, V., Wåhlin, S., Sandberg, S., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12750 · Cited by 122
Self-citationMaternal Prepregnancy Folate Intake and Risk of Spontaneous Abortion and Stillbirth
Gaskins, A. J., Rich-Edwards, J. W., Hauser, R. B., Williams, P. L., Gillman, M. W., Ginsburg, E. S., Missmer, S. A., & Chavarro, J. E. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000343 · Cited by 119
Dowman, J. K., Gunson, B. K., Mirza, D. F., Bramhall, S. R., Badminton, M. N., & Newsome, P. N. (2011) · Liver Transplantation · doi:10.1002/lt.22345 · Cited by 112
Molecular and Biochemical Studies of Acute Intermittent Porphyria in 196 Patients and Their Families
Kauppinen, R., & zu Fraunberg, M. V. U. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.11.1891 · Cited by 107
Monteiro, H. P., Abdalla, D. S. P., Faljoni‐Alário, A., & Bechara, E. J. H. (1986) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(86)90102-9 · Cited by 104
Müller, W. E., & Snyder, S. H. (1977) · Annals of Neurology · doi:10.1002/ana.410020415 · Cited by 101
Role of Delta-aminolevulinic Acid in the Symptoms of Acute Porphyria
Bissell, D. M., Lai, J. C., Meister, R., & Blanc, P. D. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.10.026 · Cited by 99
Self-citationMarsden, J. T., Guppy, S., Stein, P. E., Cox, T. M., Badminton, M. N., Gardiner, T., Barth, J. H., Stewart, M. F., & Rees, D. C. (2015) · JIMD Reports · doi:10.1007/8904_2015_411 · Cited by 82
Self-citationSimon, A. R., Pompilus, F., Querbes, W., Wei, A., Strzok, S., Penz, C., Lyon, D., Hungate, J. R., Kim, J. B., Agarwal, S., et al. (2018) · Patient · doi:10.1007/s40271-018-0319-3 · Cited by 75
Self-citationYasuda, M., Erwin, A., Liu, L. U., Balwani, M., Chen, B., Kadirvel, S., Gan, L., Fiel, M. I., Gordon, R. E., Yu, C., et al. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00099 · Cited by 68
Self-citationMarsden, J. T., & Rees, D. C. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201367 · Cited by 65
Self-citationzu Fraunberg, M. V. U., Timonen, K., Mustajoki, P., & Kauppinen, R. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200860 · Cited by 63
Management of acute intermittent porphyria
Harper, P., & Sardh, E. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.891456 · Cited by 32
Self-citationSerrano-Mendioroz, I., Sampedro, A., Alegre, M., de Salamanca, R. E., Berraondo, P., & Fontanellas, A. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.056 · Cited by 20
Tissue-specific gene silencing monitored in circulating RNA
Sehgal, A., Chen, Q., Gibbings, D., Sah, D. W. Y., & Bumcrot, D. A. (2013) · RNA · doi:10.1261/rna.042507.113 · Cited by 14
Cited by
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Self-citationThe growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Metadata
- Authors
- Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D., Bissell, D. M., Desnick, R., Parker, C., Phillips, J., Bonkovsky, H. L., Vassiliou, D., Penz, C., Chan-Daniels, A., He, Q., Querbes, W., Fitzgerald, K., Kim, J. B., Garg, P., Vaishnaw, A., Simon, A. R., & Anderson, K. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 549-558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2911904102
- Cited by
- 259
- References
- 28
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.